Novago Therapeutics is a Swiss clinical-stage company specializing in developing treatments for acute spinal cord injury and diabetic retinopathy. As a spin-off from the University of Zürich, we are currently in our Series A funding round, supported by investors such as Pureos Bioventures, Neurimmune, and non-dilutive funding sources.
We are advancing two key assets: Spinal Cord Injury (NG004) and Diabetic Retinopathy (NG050).

May 6, 15:15 - 15:30, room Montreal